Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
- PMID: 21134520
- PMCID: PMC3746516
- DOI: 10.1016/j.metabol.2010.09.010
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
Abstract
The prevalence of type 2 diabetes continues to increase at an alarming rate around the world, with even more people being affected by prediabetes. Although the pathogenesis and long-term complications of type 2 diabetes are fairly well known, its treatment has remained challenging, with only half of the patients achieving the recommended hemoglobin A(1c) target. This narrative review explores the pathogenetic rationale for the treatment of type 2 diabetes, with the view of fostering better understanding of the evolving treatment modalities. The diagnostic criteria including the role of hemoglobin A(1c) in the diagnosis of diabetes are discussed. Due attention is given to the different therapeutic maneuvers and their utility in the management of the diabetic patient. The evidence supporting the role of exercise, medical nutrition therapy, glucose monitoring, and antiobesity measures including pharmacotherapy and bariatric surgery is discussed. The controversial subject of optimum glycemic control in hospitalized and ambulatory patients is discussed in detail. An update of the available pharmacologic options for the management of type 2 diabetes is provided with particular emphasis on newer and emerging modalities. Special attention has been given to the initiation of insulin therapy in patients with type 2 diabetes, with explanation of the pathophysiologic basis for insulin therapy in the ambulatory diabetic patient. A review of the evidence supporting the efficacy of the different preventive measures is also provided.
Copyright © 2011. Published by Elsevier Inc.
Conflict of interest statement
The authors of this article do not have any conflict of interest to disclose. No part of the manuscript has been submitted or is under consideration in any other publication.
Figures
Similar articles
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.Clin Ther. 2007 Feb;29(2):316-25. doi: 10.1016/j.clinthera.2007.02.012. Clin Ther. 2007. PMID: 17472823
-
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. BMJ. 2012. PMID: 22411919
-
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.Clin Ther. 2005 Sep;27(9):1383-91. doi: 10.1016/j.clinthera.2005.09.003. Clin Ther. 2005. PMID: 16291411 Clinical Trial.
-
Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.Clin Ther. 2011 Apr;33(4):408-24. doi: 10.1016/j.clinthera.2011.04.008. Clin Ther. 2011. PMID: 21635988 Review.
Cited by
-
Knowledge, attitudes, and practices of Lebanese patients with type II diabetes towards the use and abuse of dietary supplements: A cross-sectional study.F1000Res. 2024 Jul 26;13:432. doi: 10.12688/f1000research.146998.2. eCollection 2024. F1000Res. 2024. PMID: 39108606 Free PMC article.
-
Pioglitazone acutely reduces energy metabolism and insulin secretion in rats.Diabetes. 2013 Jun;62(6):2122-9. doi: 10.2337/db12-0428. Epub 2013 Feb 1. Diabetes. 2013. PMID: 23378607 Free PMC article.
-
Prevalence and predictors of type 2 diabetes complications: a single centre observation.Afr Health Sci. 2023 Sep;23(3):308-317. doi: 10.4314/ahs.v23i3.37. Afr Health Sci. 2023. PMID: 38357114 Free PMC article.
-
Decreased cardiovascular risk factors and inflammation with remission of type 2 diabetes in adults with obesity using a high protein diet: Randomized control trial.Obes Pillars. 2022 Dec 1;4:100047. doi: 10.1016/j.obpill.2022.100047. eCollection 2022 Dec. Obes Pillars. 2022. PMID: 37990670 Free PMC article.
-
Development of a Deep Learning Model for Dynamic Forecasting of Blood Glucose Level for Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.JMIR Mhealth Uhealth. 2019 Nov 1;7(11):e14452. doi: 10.2196/14452. JMIR Mhealth Uhealth. 2019. PMID: 31682586 Free PMC article. Clinical Trial.
References
-
- De Fronzo RA. Lilly lecture 1987. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–87. - PubMed
-
- Centers for Disease Control. National Diabetes Fact Sheet. 2007 Accessed online at www.cdc.gov/diabetes/pubs/fact-sheet07.htm on December 2, 2009.
-
- Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–9. - PubMed
-
- Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism. 1988;37(2 Suppl 1):1–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical